Stockreport

Adagene Spotlights ADG126 at Leerink, Teases New MSS Colorectal Cancer Data Update Soon [Yahoo! Finance]

Adagene Inc. - ADS, each representing 1.25 ordinary shares  (ADAG) 
PDF colorectal cancer—well above a cited 2.5% ORR for nivolumab+ipilimumab—and Adagene says it will release an updated doublet dataset in the coming weeks to add patients an [Read more]